Insight Molecular Diagnostics Inc. (IMDX) Financial Analysis & Valuation | Quarter Chart

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and ... more
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes prop... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$129.16MExchangeNASDAQ
SectorHealthcareIndustryMedical - Diagnostics & Research
CountryUSCEOJoshua Riggs
IPO Date2015-12-30CAGR
Employees57Websiteimdxinc.com
Div. YieldPayout Ratio
Buy Back YieldTotal Yield
IMDX chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$187.32MP/E-2.68Forward P/E-5PEG
P/S12.37P/B-1.11P/CF-0.87P/FCF-0.7
Sales$1.67MSales 1Y-60.77%Sales 3Y51.68%Sales 5Y-60.35%
EPS$-1.49EPS 1Y-56.27%EPS 3Y-84.65%EPS 5Y-79.15%
Sales QoQ646.88%EPS QoQ158.33%Sales QoQ Avg209.49%EPS QoQ Avg51.67%
Gross Margin11.17%Operating Margin-2558.74%Profit Margin-2955.63%ROCE-223.06%
ROA-168%ROE272%Altman Z Score-23.19Piotroski Score1
Current Ratio2Quick Ratio1.98Cash Ratio1.73Op. CF Ratio-0.9
Debt/Equity-0.12Debt/Assets0.09Lt Debt/Equity-0.04Lt Debt/Cap.-0.04
Intrst Cov.-436.03Inventory Turnover7.17Asset Turnover0.06Receivables Turnover8.7
Enterprise Value$187.32MP/E Ratio-2.68
Forward P/E-5PEG Ratio
P/S Ratio12.37P/B Ratio-1.11
P/CF Ratio-0.87P/FCF Ratio-0.7
EPS$-1.49EPS Growth 1Y-56.27%
EPS Growth 3Y-84.65%EPS Growth 5Y-79.15%
Revenue Growth 1Y-60.77%Gross Margin11.17%
Operating Margin-2558.74%Profit Margin-2955.63%
ROE272%ROA-168%
ROCE-223.06%Current Ratio2
Quick Ratio1.98Cash Ratio1.73
Debt/Equity-0.12Interest Coverage-436.03
Altman Z Score-23.19Piotroski Score1